MarketCapExport financials
TFF Pharmaceuticals (TFFP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
TFF Pharmaceuticals Cash Flow 2023-2011 | TFFP
Brief overview of TFF Pharmaceuticals's cash generation
The comparison covers five available annual reports between 2019 and 2023.
Operating cash flow is negative at -$16 million, leaving internal funding capacity weak.
Only 0 of five annual observations were positive, indicating weak repeatability.
Cash flow takeaway
TFF Pharmaceuticals's cash profile looks stretched: weak operating cash flow limits investment, payouts and debt-servicing capacity.
Annual Cash Flow TFF Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-16 M | -27.3 M | -29.6 M | -16.6 M | -11.2 M | -2.13 M | - | - | - | - | - | - | - |
Depreciation & Amortization |
502 K | 388 K | 111 K | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
958 K | 920 K | 1.49 M | 1.3 M | 411 K | 429 K | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow TFF Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-8.38 M | -6.4 M | -3.14 M | - | -11.8 M | -8.82 M | -4.37 M | - | -19.6 M | -12.3 M | -7.25 M | - | -18.7 M | -11.5 M | -5.59 M | - | -10.4 M | -6.13 M | -2.35 M | - | -6.91 M | -3.84 M | -2.12 M | - | -1.34 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
422 K | 281 K | 140 K | - | 372 K | 247 K | 123 K | - | 267 K | 166 K | 77 K | - | 34.4 K | 5.98 K | 1.5 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
1.64 M | 1.36 M | 1.66 M | 958 K | 983 K | 1.01 M | 1.34 M | 920 K | 1.63 M | 3.48 M | 2.03 M | 1.49 M | 1.56 M | 1.51 M | 1.82 M | 1.3 M | 1.57 M | 690 K | 1.2 M | 411 K | 691 K | 411 K | 411 K | 429 K | 429 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company TFF Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Anavex Life Sciences Corp.
AVXL
|
$ 1.31 | 1.01 % | $ 112 M |  USA |
 |
Syros Pharmaceuticals
SYRS
|
- | -8.44 % | $ 3.4 M | USA |
 |
Bio-Techne Corporation
TECH
|
$ 72.57 | 0.07 % | $ 11.3 B | USA |
 |
Tenax Therapeutics
TENX
|
$ 1.36 | 0.65 % | $ 53.3 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
$ 41.5 | 0.95 % | $ 47.5 B |  Israel |
 |
TG Therapeutics
TGTX
|
$ 53.97 | 3.0 % | $ 7.79 B | USA |
 |
Gossamer Bio
GOSS
|
$ 8.77 | 0.11 % | $ 2 B | USA |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
$ 6.04 | 0.31 % | $ 51.4 M | USA |
 |
Trevi Therapeutics
TRVI
|
$ 11.88 | 0.41 % | $ 1.6 B | USA |
 |
Gamida Cell Ltd.
GMDA
|
- | -18.25 % | $ 5.04 M | Israel |
 |
Taysha Gene Therapies
TSHA
|
$ 3.62 | 6.27 % | $ 1.16 B | USA |
 |
Innoviva
INVA
|
$ 20.78 | 0.19 % | $ 1.4 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
$ 34.56 | 0.08 % | $ 1.66 B | Israel |
 |
United Therapeutics Corporation
UTHR
|
$ 533.12 | 0.27 % | $ 23.6 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.21 | 0.4 % | $ 9.6 M | Israel |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | USA |
 |
Vericel Corporation
VCEL
|
$ 40.13 | 0.33 % | $ 2.02 B | USA |
 |
Veracyte
VCYT
|
$ 43.12 | 1.16 % | $ 3.39 B | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
$ 3.5 | 4.72 % | $ 566 M | USA |
 |
Vir Biotechnology
VIR
|
$ 9.96 | 0.58 % | $ 1.38 B | USA |
 |
Viking Therapeutics
VKTX
|
$ 25.17 | 7.46 % | $ 2.84 B | USA |
 |
Vanda Pharmaceuticals
VNDA
|
$ 4.04 | 0.24 % | $ 238 M | USA |
 |
Genmab A/S
GMAB
|
$ 37.0 | 0.33 % | $ 2.39 B |  Danmark |
 |
Verrica Pharmaceuticals
VRCA
|
$ 3.6 | 0.79 % | $ 38.3 M | USA |
 |
Viridian Therapeutics
VRDN
|
$ 19.03 | 0.92 % | $ 1.94 B | USA |
 |
Inventiva S.A.
IVA
|
$ 2.94 | 8.36 % | $ 176 M |  France |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.46 | 0.02 % | $ 5.09 M | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | USA |
 |
Verastem
VSTM
|
$ 8.65 | 0.05 % | $ 600 M | USA |
 |
VistaGen Therapeutics
VTGN
|
$ 0.2 | 3.1 % | $ 7.61 M | USA |
 |
vTv Therapeutics
VTVT
|
$ 26.54 | 0.25 % | $ 105 M | USA |
 |
Voyager Therapeutics
VYGR
|
$ 1.9 | 2.49 % | $ 112 M | USA |
 |
Genprex
GNPX
|
$ 2.11 | 1.31 % | $ 1.97 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
$ 3.13 | 0.78 % | $ 528 M |  Singapore |
 |
Agenus
AGEN
|
$ 6.04 | 2.77 % | $ 180 M | USA |
 |
Xenetic Biosciences
XBIO
|
$ 1.98 | 0.48 % | $ 3.37 M | USA |
 |
Keros Therapeutics
KROS
|
$ 10.66 | 0.45 % | $ 397 M | USA |
|
XBiotech
XBIT
|
$ 2.12 | 1.67 % | $ 64.6 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
$ 33.49 | 1.27 % | $ 2.65 B |  Canada |
 |
Xeris Pharmaceuticals
XERS
|
$ 10.31 | 2.38 % | $ 1.65 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
$ 2.59 | 0.19 % | $ 110 M | USA |
 |
Kodiak Sciences
KOD
|
$ 85.75 | 0.64 % | $ 4.56 B | USA |
 |
22nd Century Group
XXII
|
$ 0.34 | 0.98 % | $ 62.6 K | USA |
 |
Halozyme Therapeutics
HALO
|
$ 121.84 | 0.27 % | $ 14.6 B | USA |
 |
Arvinas
ARVN
|
$ 6.97 | 1.12 % | $ 494 M | USA |
 |
Zai Lab Limited
ZLAB
|
$ 23.19 | 0.79 % | $ 25.4 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
$ 2.13 | 0.83 % | $ 153 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.6 | 1.78 % | $ 426 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
$ 66.39 | 3.37 % | $ 12.7 B | USA |